Solésence, Inc. (Nasdaq: SLSN), a leader in health care solutions across beauty and life science categories, announced on June 2, 2025, that it has amended its existing loan agreements to expand borrowing capacity. The amendments, made on May 27, 2025, increase the maximum borrowing capacity from $14.2 million to $23.0 million and extend the maturity date from October 1, 2025, to April 30, 2027. This enhanced financial flexibility will support Solésence's strategic objectives, including raw material procurement, packaging improvements, and product launches. CEO Jess Jankowski expressed gratitude for the support from banking partners and stakeholders, emphasizing the importance of this development in scaling operations and serving brand partners.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。